[1]
|
Stern, L., McGuire, H., Avdic, S., et al. (2018) Mass Cytometry for the Assessment of Immune Reconstitution after Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 9, Article No. 1672.
https://doi.org/10.3389/fimmu.2018.01672
|
[2]
|
刘洋. 异基因造血干细胞移植患者免疫细胞恢复监测及临床意义[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2015.
|
[3]
|
陈凯. 异基因造血干细胞移植后免疫重建的研究进展[J]. 国际儿科学杂志, 2020, 47(2): 96-99.
|
[4]
|
Bishop, M.-R., Alyea, E.P.-Rd., Cairo, M.-S., et al. (2011) Na-tional Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Alloge-neic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 17, 443-454.
https://doi.org/10.1016/j.bbmt.2010.12.713
|
[5]
|
Strasfeld, L. (2022) COVID-19 and HSCT (Hematopoietic Stem Cell Transplant). Best Practice & Research Clinical Haematology, 35, Article ID: 101399. https://doi.org/10.1016/j.beha.2022.101399
|
[6]
|
Guo, W.-W., Liu, X., Pang, A.-M., et al. (2021) Analysis of Risk Factors of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with t (8;21) Acute Myeloid Leukemia. Chinese Journal of Hematology, 42, 998-1004.
|
[7]
|
刘建宁. PD-1、TIM-3、LAG-3在急性白血病异基因造血干细胞移植后T淋巴细胞的表达及意义初探[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2020.
|
[8]
|
Takaku, S., Shimizu, M. and Morita, R. (2023) CD8(+) T Cell-Mediated Therapeutic Antitumor Effect of an Herbal Mixture Containing Ganoderma lucidum. Evidence-Based Complementary and Alternative Medicine, 2023, Arti-cle ID: 9630816. https://doi.org/10.1155/2023/9630816
|
[9]
|
Velardi, E., Tsai, J.-J. and van den Brink, M.R.M. (2021) T Cell Regeneration after Immunological Injury. Nature Reviews Immunology, 21, 277-291. https://doi.org/10.1038/s41577-020-00457-z
|
[10]
|
Omer, A.-K., Ziakas, P.-D., Anagnostou, T., et al. (2013) Risk Factors for Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experi-ence. Biology of Blood and Marrow Transplantation, 19, 1190-1196. https://doi.org/10.1016/j.bbmt.2013.05.018
|
[11]
|
Seggewiss, R. and Einsele, H. (2010) Immune Reconstitution after Allogeneic Transplantation and Expanding Options for Immunomodulation: An Update. Blood, 115, 3861-3868. https://doi.org/10.1182/blood-2009-12-234096
|
[12]
|
van der Maas, N.-G., Berghuis, D., van der Burg, M., et al. (2019) B Cell Reconstitution and Influencing Factors after Hematopoietic Stem Cell Transplantation in Children. Fron-tiers in Immunology, 10, Article No. 782.
https://doi.org/10.3389/fimmu.2019.00782
|
[13]
|
Stern, L., McGuire, H., Avdic, S., et al. (2018) Mass Cytometry for the Assessment of Immune Reconstitution after Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 9, Article No. 1672.
https://doi.org/10.3389/fimmu.2018.01672
|
[14]
|
Chamoun, K., Milton, D.-R., Ledesma, C., et al. (2019) Allogeneic Transplantation after Myeloablative Rituximab/BEAM+/− Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biology of Blood and Marrow Transplantation, 25, 1347-1354. https://doi.org/10.1016/j.bbmt.2019.02.022
|
[15]
|
van der Maas, N.-G., Berghuis, D., van der Burg, M., et al. (2019) B Cell Reconstitution and Influencing Factors after Hematopoietic Stem Cell Transplantation in Children. Frontiers in Immunology, 10, Article No. 782.
https://doi.org/10.3389/fimmu.2019.00782
|
[16]
|
Abdel-Azim, H., Elshoury, A., Mahadeo, K.-M., et al. (2017) Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Mat-uration Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution. Biology of Blood and Marrow Transplantation, 23, 1437-1446.
https://doi.org/10.1016/j.bbmt.2017.05.005
|
[17]
|
Kroger, N., Zagrivnaja, M., Schwartz, S., et al. (2006) Kinetics of Plasma-Cell Chimerism after Allogeneic Stem Cell Transplantation by Highly Sensitive Real-Time PCR Based on Se-quence Polymorphism and Its Value to Quantify Minimal Residual Disease in Patients with Multiple Myeloma. Experi-mental Hematology, 34, 688-694.
https://doi.org/10.1016/j.exphem.2006.01.011
|
[18]
|
Abrahamsen, I.-W., Somme, S., Heldal, D., et al. (2005) Im-mune Reconstitution after Allogeneic Stem Cell Transplantation: The Impact of Stem Cell Source and Graft-versus-Host Disease. Haematologica, 90, 86-93.
|
[19]
|
Gianchecchi, E., Delfino, D.-V. and Fierabracci, A. (2013) Recent Insights in-to the Role of the PD-1/PD-L1 Pathway in Immunological Tolerance and Autoimmunity. Autoimmunity Reviews, 12, 1091-1100.
https://doi.org/10.1016/j.autrev.2013.05.003
|
[20]
|
陈晓晨. PD-1和TIM-3在耗竭T细胞介导B系淋巴瘤免疫逃逸中的作用机制及临床应用研究[D]: [博士学位论文]. 苏州: 苏州大学, 2020.
|
[21]
|
刘建宁, 孙立, 牛志云, 等. PD-1在急性白血病异基因造血干细胞移植后T淋巴细胞的表达[J]. 临床荟萃, 2021, 36(3): 251-255.
|
[22]
|
Simonetta, F., Pradier, A., Bosshard, C., et al. (2019) Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells after Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 10, Article No. 1034. https://doi.org/10.3389/fimmu.2019.01034
|
[23]
|
Michonneau, D., Sagoo, P., Breart, B., et al. (2016) The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity That Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation. Immunity, 44, 143-154.
https://doi.org/10.1016/j.immuni.2015.12.008
|
[24]
|
Haverkos, B.-M., Abbott, D., Hamadani, M., et al. (2017) PD-1 Blockade for Relapsed Lymphoma Post-Allogeneic Hematopoietic Cell Transplant: High Response Rate but Frequent GVHD. Blood, 130, 221-228.
https://doi.org/10.1182/blood-2017-01-761346
|
[25]
|
Monney, L., Sabatos, C.A., Gaglia, J.L., et al. (2002) Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease. Nature, 415, 536-541. https://doi.org/10.1038/415536a
|
[26]
|
Acharya, N., Sabatos-Peyton, C. and Anderson, A.-C. (2020) Tim-3 Finds Its Place in the Cancer Immunotherapy Landscape. The Journal for ImmunoTherapy of Cancer, 8, e000911. https://doi.org/10.1136/jitc-2020-000911
|
[27]
|
Kuai, W., Xu, X., Yan, J., et al. (2020) Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer. BioMed Research International, 2020, Article ID: 5294043.
https://doi.org/10.1155/2020/5294043
|
[28]
|
Khalaf, S., Toor, S.-M., Murshed, K., et al. (2020) Differential Expres-sion of TIM-3 in Circulation and Tumor Microenvironment of Colorectal Cancer Patients. Clinical Immunology, 215, Ar-ticle ID: 108429.
https://doi.org/10.1016/j.clim.2020.108429
|
[29]
|
Joller, N. and Kuchroo, V.-K. (2017) Tim-3, Lag-3, and TIGIT. In: Yoshimura, A., Ed., Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity, Vol. 410, Springer, Berlin, 127-156.
https://doi.org/10.1007/82_2017_62
|
[30]
|
田金, 张腾龙, 李玲, 等. LAG-3分子的研究进展[J]. 新医学, 2020, 51(9): 663-666.
|
[31]
|
Sega, E.-I., Leveson-Gower, D.-B., Florek, M., et al. (2014) Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation. PLOS ONE, 9, e86551.
https://doi.org/10.1371/journal.pone.0086551
|
[32]
|
Brown, E.-J. and Frazier, W.-A. (2001) Integrin-Associated Protein (CD47) and Its Ligands. Trends in Cell Biology, 11, 130-135. https://doi.org/10.1016/S0962-8924(00)01906-1
|
[33]
|
尹松梅, 康颖. CD47生理功能的研究[J]. 中国实验血液学杂志, 2003, 11(4): 437-440.
|
[34]
|
武倩, 周芳, 解琳娜, 等. allo-HSCT后急性GVHD患者外周血中T淋巴细胞CD47表达变化的观察[J]. 中华器官移植杂志, 2016, 37(5): 275-279.
|
[35]
|
黄盼盼, 张爱梅, 张翠萍, 等. 外周血干细胞移植与非血缘脐带血移植的患者免疫重建规律的比较[J]. 中华检验医学杂志, 2021, 44(12): 1138-1144.
|
[36]
|
Hoffmeister, P.A., Storer, B.E., Macris, P.C., et al. (2013) Relationship of Body Mass Index and Arm Anthropometry to Outcomes after Pediatric Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 19, 1081-1086. https://doi.org/10.1016/j.bbmt.2013.04.017
|
[37]
|
Hess, A.-D. (2010) Reconstitution of Self-Tolerance after Hema-topoietic Stem Cell Transplantation. Immunology Research, 47, 143-152. https://doi.org/10.1007/s12026-009-8145-2
|
[38]
|
Nakashima, A., Carrero, J.-J., Qureshi, A.-R., et al. (2010) Effect of Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) and the Proinflammatory RAGE Ligand (EN-RAGE, S100A12) on Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology, 5, 2213-2219.
https://doi.org/10.2215/CJN.03360410
|
[39]
|
Ando, T., Tachibana, T., Tanaka, M., et al. (2020) Impact of Graft Sources on Immune Reconstitution and Survival Outcomes Following Allogeneic Stem Cell Transplantation. Blood Ad-vances, 4, 408-419.
https://doi.org/10.1182/bloodadvances.2019001021
|
[40]
|
Cham, L.-B., Torrez Dulgeroff, L.B., Tal, M.-C., et al. (2020) Immunotherapeutic Blockade of CD47 Inhibitory Signaling Enhances Innate and Adaptive Immune Responses to Viral Infection. Cell Reports, 31, Article ID: 107494.
https://doi.org/10.1016/j.celrep.2020.03.058
|
[41]
|
Annaloro, C., Serpenti, F., Saporiti, G., et al. (2020) Viral Infec-tions in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications. Frontiers in Immunology, 11, Article ID: 569381.
https://doi.org/10.3389/fimmu.2020.569381
|
[42]
|
Miyashita, M., Shimizu, T., Ashihara, E., et al. (2021) Strategies to Improve the Antitumor Effect of Gammadelta T Cell Immunotherapy for Clinical Application. International Journal of Molecular Sciences, 22, Article No. 8910.
https://doi.org/10.3390/ijms22168910
|
[43]
|
Ciceri, F., Bacigalupo, A., Lankester, A., et al. (2019) Haploidentical HSCT. In: Carreras, E., Dufour, C., Mohty, M. and Kröger, N., Eds., The EBMT Handbook, Springer, Berlin, 479-486. https://doi.org/10.1007/978-3-030-02278-5_65
|
[44]
|
Storb, R. (2019) HSCT: Historical Perspective. In: Carreras, E., Dufour, C., Mohty, M. and Kröger, N., Eds., The EBMT Handbook, Springer, Berlin, 3-9. https://doi.org/10.1007/978-3-030-02278-5_1
|
[45]
|
Reisner, Y. (2019) Haploidentical HSCT—Going from Strength to Strength. Bone Marrow Transplantation, 54, 687-688.
https://doi.org/10.1038/s41409-019-0593-2
|